Allozyne Inc.
This article was originally published in Start Up
Executive Summary
Allozyne Inc.'s novel interferon beta drug candidate is now in Phase I clinical trials for MS. The company used its proprietary linker technology to attach PEG to interferon, and believes that will allow more drug to be loaded into a dose and lead to a product that could be injected as infrequently as once per month. Moreover, it thinks its PEG conjugate should reduce tolerance problems and improve half-life over current interferons.